Literature DB >> 8538929

Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects.

G Graziani1, G Como, S Badalamenti, S Finazzi, A Malesci, M Gallieni, D Brancaccio, C Ponticelli.   

Abstract

BACKGROUND: Phosphate-induced hyperparathyroidism still represents an intriguing problem in dialysis patients. Postprandial hyperphosphataemia is considered to be the main stimulus to parathyroid hyperfunction, and therefore many efforts have focused on the use of phosphate binders to prevent phosphate absorption.
METHODS: We investigated whether the pH-mediated gastric ionization of calcium phosphate dietary salts is necessary for its intestinal absorption. In eight normal subjects we measured 24-h urinary calcium phosphate excretion and the postprandial blood calcium phosphate profile after a meal containing 1 g of calcium and 2 g of phosphate salts in a crossover placebo-omeprazole study. On two occasions the subjects received either placebo or omeprazole 60 mg/day 2 days before and during the day test.
RESULTS: Serum gastrin levels were measured as an indicator of achlorhydria and were 13.7 +/- 1 pg/ml after placebo and 30.4 +/- 4.7 after omeprazole (P < 0.003). Postprandial plasma phosphate profiles were not significantly different between the two studies (+36 +/- 8% after placebo and +24 +/- 8% after omeprazole, NS), while plasma calcium increased by +6.1 +/- 1% after placebo and decreased by -4.2 +/- 0.7% after omeprazole (P < 0.01). The 24-h urinary phosphate excretion was 1068 +/- 85 mg after placebo and 773 +/- 55 after omeprazole (P < 0.002), while the 24-h urinary calcium excretion was 360 +/- 21 after placebo and 238 +/- 15 after omeprazole (P < 0.0001). A negative relationship was observed between absolute changes in plasma gastrin and those in urinary calcium (P < 0.009) and phosphate (P < 0.05).
CONCLUSIONS: The inhibition of gastric acid secretion by omeprazole significantly reduces both urinary phosphate and calcium excretion after an oral load. The behaviour of the postprandial calcium-phosphate plasma profile suggests that gastric acid inhibition is more effective in reducing calcium rather than phosphate dietary salts absorption in normal subjects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8538929

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  17 in total

1.  Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.

Authors:  Shelly L Gray; Andrea Z LaCroix; Joseph Larson; John Robbins; Jane A Cauley; JoAnn E Manson; Zhao Chen
Journal:  Arch Intern Med       Date:  2010-05-10

Review 2.  Safety of proton pump inhibitors: current evidence for osteoporosis and interaction with antiplatelet agents.

Authors:  David A Johnson
Journal:  Curr Gastroenterol Rep       Date:  2010-06

Review 3.  Update on medications with adverse skeletal effects.

Authors:  Caroline J Davidge Pitts; Ann E Kearns
Journal:  Mayo Clin Proc       Date:  2011-03-09       Impact factor: 7.616

4.  Hip fracture risk in patients with a diagnosis of pernicious anemia.

Authors:  Nathan A Merriman; Mary E Putt; David C Metz; Yu-Xiao Yang
Journal:  Gastroenterology       Date:  2009-12-21       Impact factor: 22.682

Review 5.  The role of the gastrointestinal tract in calcium homeostasis and bone remodeling.

Authors:  J Keller; T Schinke
Journal:  Osteoporos Int       Date:  2013-03-28       Impact factor: 4.507

6.  Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.

Authors:  Douglas A Corley; Ai Kubo; Wei Zhao; Charles Quesenberry
Journal:  Gastroenterology       Date:  2010-03-27       Impact factor: 22.682

Review 7.  Chronic proton pump inihibitor therapy and calcium metabolism.

Authors:  Yu-Xiao Yang
Journal:  Curr Gastroenterol Rep       Date:  2012-12

Review 8.  Proton pump inhibitors and fracture risk: true effect or residual confounding?

Authors:  Michael Bodmer; Christian Meier; Marius E Kraenzlin; Christoph R Meier
Journal:  Drug Saf       Date:  2010-10-01       Impact factor: 5.606

Review 9.  Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Gastroenterol Rep       Date:  2010-12

10.  Acid-suppressive medications and risk of bone loss and fracture in older adults.

Authors:  Elaine W Yu; Terri Blackwell; Kristine E Ensrud; Teresa A Hillier; Nancy E Lane; Eric Orwoll; Douglas C Bauer
Journal:  Calcif Tissue Int       Date:  2008-09-24       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.